Peggy Afua Birikorang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peggy Afua Birikorang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gary Kohanbash
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
2 shared publications - Wilson Barry Edwards
Department of Biochemistry, University of Missouri, Columbia, Missouri
2 shared publications Abigail Anning
Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
1 shared publication- Anastasia Rosebud Aikins
West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
1 shared publication Dominic M. Menendez
Department of Biochemistry, University of Missouri-Columbia, 503 S College Avenue, Columbia, Missouri 65211, United States
1 shared publication- Eunice Dotse
Department of Biomedical Sciences, City University of Hong Kong, Kowloon, China
1 shared publication
Latest Publications
- 19 September 2025
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (6) , 993-1005
Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer
Purpose In this study, we report the development and characterization of a copper-64 (64Cu) radiolabeled anti-EphA2 minibody (Mb) for pre-treatment characterization of antigen expression via Positron Emission Tomography (PET). Minibodies, ≈85 kDa molecular weight antibody fragments, are advantageous as targeting molecules due to accelerated serum clearance which enables imaging at earlier time points relative to the parent IgG. As EphA2, a tyrosine kinase receptor, is overexpressed in various cancer types with minimal expression in normal tissue, rapid quantification of EphA2 expression could be beneficial for patient stratification. Procedures. Recombinantly produced anti-EphA2-Mb was evaluated for purity, stability, affinity, and in vivo target localization. Following bifunctional chelator conjugation, radiolabeling with 64Cu and evaluating purity, stability and immunoreactivity of resultant radioimmunoconjugate, [64Cu]Cu-NOTA-anti-EphA2-Mb, 11.1 MBq (300 μCi) and 0.2 MBq (5 μCi) doses were administered to HT1080-fibrosarcoma-bearing nude mice for in-vivo PET imaging and ex-vivo biodistribution analyses respectively at 4 and 24 h post-injection (p.i.). Antigen-specificity was assessed via a blocked control group which received the dose co-administered with non-radiolabeled anti-EphA2-Mb. Results Anti-EphA2-Mb produced via recombinant protein expression was pure, stable and had high binding affinity to human EphA2 antigen (KD = 0.63 ± 0.24 nM). When labeled with 64Cu via NOTA, [64Cu]Cu-NOTA-anti-EphA2-Mb had high purity, in-vitro stability in PBS and mouse serum up to 24 h, and high immunoreactivity. On administering to tumor-bearing mice, [64Cu]Cu-NOTA-anti-EphA2-Mb exhibited rapid tumor targeting with 25.53±2.92%ID/g at 4 h, and 22.13±7.68%ID/g at 24 h p.i. Competitive inhibition reduced tumor uptake (11.24±0.88%D/g, 24 h p.i., p = 0.0286). There was minimal uptake of the radiotracer in non-target tissues, except kidney and liver, and fast clearance from the blood, with high tumor to blood ratios. Tumor SUVmean values obtained from region of interest (ROI) Quantification of the PET images were 1.13±0.03 and 1.08±0.06 at 4 and 24 h respectively. Conclusion Our findings demonstrate that anti-EphA2-Mb is an excellent targeting molecule, and [64Cu]Cu-NOTA-anti-EphA2-Mb is a promising immunoPET agent with potential for use for other theranostic applications.
- 19 September 2025
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (6) , 993-1005
Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer
Purpose In this study, we report the development and characterization of a copper-64 (64Cu) radiolabeled anti-EphA2 minibody (Mb) for pre-treatment characterization of antigen expression via Positron Emission Tomography (PET). Minibodies, ≈85 kDa molecular weight antibody fragments, are advantageous as targeting molecules due to accelerated serum clearance which enables imaging at earlier time points relative to the parent IgG. As EphA2, a tyrosine kinase receptor, is overexpressed in various cancer types with minimal expression in normal tissue, rapid quantification of EphA2 expression could be beneficial for patient stratification. Procedures. Recombinantly produced anti-EphA2-Mb was evaluated for purity, stability, affinity, and in vivo target localization. Following bifunctional chelator conjugation, radiolabeling with 64Cu and evaluating purity, stability and immunoreactivity of resultant radioimmunoconjugate, [64Cu]Cu-NOTA-anti-EphA2-Mb, 11.1 MBq (300 μCi) and 0.2 MBq (5 μCi) doses were administered to HT1080-fibrosarcoma-bearing nude mice for in-vivo PET imaging and ex-vivo biodistribution analyses respectively at 4 and 24 h post-injection (p.i.). Antigen-specificity was assessed via a blocked control group which received the dose co-administered with non-radiolabeled anti-EphA2-Mb. Results Anti-EphA2-Mb produced via recombinant protein expression was pure, stable and had high binding affinity to human EphA2 antigen (KD = 0.63 ± 0.24 nM). When labeled with 64Cu via NOTA, [64Cu]Cu-NOTA-anti-EphA2-Mb had high purity, in-vitro stability in PBS and mouse serum up to 24 h, and high immunoreactivity. On administering to tumor-bearing mice, [64Cu]Cu-NOTA-anti-EphA2-Mb exhibited rapid tumor targeting with 25.53±2.92%ID/g at 4 h, and 22.13±7.68%ID/g at 24 h p.i. Competitive inhibition reduced tumor uptake (11.24±0.88%D/g, 24 h p.i., p = 0.0286). There was minimal uptake of the radiotracer in non-target tissues, except kidney and liver, and fast clearance from the blood, with high tumor to blood ratios. Tumor SUVmean values obtained from region of interest (ROI) Quantification of the PET images were 1.13±0.03 and 1.08±0.06 at 4 and 24 h respectively. Conclusion Our findings demonstrate that anti-EphA2-Mb is an excellent targeting molecule, and [64Cu]Cu-NOTA-anti-EphA2-Mb is a promising immunoPET agent with potential for use for other theranostic applications.
- Open Access
- 28 May 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (6) , 1208-1217
Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody
Targeting molecules, such as antibodies and peptides, play a key role in the precise delivery of cytotoxic payloads to tumor sites by binding to specific tumor-associated antigens or other proteins within the tumor microenvironment. This investigation evaluates the potential therapeutic application of a bispecific antibody (BsAb), which simultaneously targets EphA2, a tumor-associated antigen, and CD11b, a protein expressed by tumor-associated macrophages and myeloid-derived suppressor cells (TAMCs). Recombinantly produced anti-EphA2-CD11b-BsAb was conjugated to a bifunctional chelator, NOTA-SCN, and then radiolabeled with copper-64 (64Cu). The [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb radioimmunoconjugate was subsequently administered to HT1080-fibrosarcoma-bearing nude mice via tail vein injection. Positron Emission Tomography (PET) and ex vivo biodistribution analyses were performed to determine tumor uptake and pharmacokinetic localization. At 4, 24, and 48 h postinjection (p.i.), the percent injected dose per gram (%ID/g) of [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb in HT1080 xenografts were 5.35 ± 2.24, 4.44 ± 1.90, and 4.10 ± 0.60, respectively. There was high uptake in the liver as well as in CD11b-expressing organs, including the spleen, bone marrow, and lung. Binding in these CD11b-rich organs was significantly reduced by coadministering the dose with nonradiolabeled anti-CD11b-IgG and anti-EphA2-CD11b-BsAb, with a concurrent increase in tumor uptake compared to nonblocked mice (8.39 ± 1.37%ID/g for blocked and 4.44 ± 1.90%ID/g for nonblocked at 24 h p.i., p = 0.0175). Further optimization studies showed that at lower molar activity (3.7 MBq/nmol, 100 μCi/nmol), there were significantly higher tumor accumulations and reduced uptake in CD11b-expressing organs compared to higher molar activity (22.2 MBq/nmol, 600 μCi/nmol). Anti-EphA2-CD11b-BsAb is a functional targeting molecule and would require optimization through molar activity or blocking with nonradiolabeled antibody to maximize tumor targeting.
- 28 May 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (6) , 1208-1217
Open AccessDeveloping and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody
Targeting molecules, such as antibodies and peptides, play a key role in the precise delivery of cytotoxic payloads to tumor sites by binding to specific tumor-associated antigens or other proteins within the tumor microenvironment. This investigation evaluates the potential therapeutic application of a bispecific antibody (BsAb), which simultaneously targets EphA2, a tumor-associated antigen, and CD11b, a protein expressed by tumor-associated macrophages and myeloid-derived suppressor cells (TAMCs). Recombinantly produced anti-EphA2-CD11b-BsAb was conjugated to a bifunctional chelator, NOTA-SCN, and then radiolabeled with copper-64 (64Cu). The [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb radioimmunoconjugate was subsequently administered to HT1080-fibrosarcoma-bearing nude mice via tail vein injection. Positron Emission Tomography (PET) and ex vivo biodistribution analyses were performed to determine tumor uptake and pharmacokinetic localization. At 4, 24, and 48 h postinjection (p.i.), the percent injected dose per gram (%ID/g) of [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb in HT1080 xenografts were 5.35 ± 2.24, 4.44 ± 1.90, and 4.10 ± 0.60, respectively. There was high uptake in the liver as well as in CD11b-expressing organs, including the spleen, bone marrow, and lung. Binding in these CD11b-rich organs was significantly reduced by coadministering the dose with nonradiolabeled anti-CD11b-IgG and anti-EphA2-CD11b-BsAb, with a concurrent increase in tumor uptake compared to nonblocked mice (8.39 ± 1.37%ID/g for blocked and 4.44 ± 1.90%ID/g for nonblocked at 24 h p.i., p = 0.0175). Further optimization studies showed that at lower molar activity (3.7 MBq/nmol, 100 μCi/nmol), there were significantly higher tumor accumulations and reduced uptake in CD11b-expressing organs compared to higher molar activity (22.2 MBq/nmol, 600 μCi/nmol). Anti-EphA2-CD11b-BsAb is a functional targeting molecule and would require optimization through molar activity or blocking with nonradiolabeled antibody to maximize tumor targeting.
- Open Access
- 19 July 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Antiproliferative Activities of Methanolic Extract and Fractions of Tetrapleura Tetraptera Fruit
Most of the current cancer chemotherapeutics are associated with harsh and undesirable side effects, including toxicity and chemoresistance, driving the need for safer and more effective alternatives. In this study, the antiproliferative activities of the methanolic extract of Tetrapleura tetraptera fruits and nine different fractions (C1C9) from the column chromatographic separation of the extract against leukemia (Jurkat) and human breast cancer (MCF-7) cell lines were investigated using a tetrazolium-based colorimetric assay. Phytochemical screening of the extract and fractions found alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, steroids, tannins, and terpenoids in the methanolic extract. Most of the fractions exhibited antiproliferative activity (>100μg/mL) with the Jurkat cells being more susceptible than the MCF-7 cells. Four of the collected fractions C4, C3, C5, and C2 had good selective indices in decreasing order of activity, in the case of Jurkat cells. Liquid chromatography-mass spectrometry analysis of all samples (except for C4 and C9) revealed that C1, C2, C3, and C5 each had a single component. More importantly, fractions C2, C3, and C5, which were selective to Jurkat cells, also had the same retention time of 1.846min. Fractions C6 and C8 had two components, with C7 having four components. This study serves as a basis for further work to isolate and characterize potential anticancer agents from the fractions of extracts of T. tetraptera fruits.
- 19 July 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Open AccessAntiproliferative Activities of Methanolic Extract and Fractions of Tetrapleura Tetraptera Fruit
Most of the current cancer chemotherapeutics are associated with harsh and undesirable side effects, including toxicity and chemoresistance, driving the need for safer and more effective alternatives. In this study, the antiproliferative activities of the methanolic extract of Tetrapleura tetraptera fruits and nine different fractions (C1C9) from the column chromatographic separation of the extract against leukemia (Jurkat) and human breast cancer (MCF-7) cell lines were investigated using a tetrazolium-based colorimetric assay. Phytochemical screening of the extract and fractions found alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, steroids, tannins, and terpenoids in the methanolic extract. Most of the fractions exhibited antiproliferative activity (>100μg/mL) with the Jurkat cells being more susceptible than the MCF-7 cells. Four of the collected fractions C4, C3, C5, and C2 had good selective indices in decreasing order of activity, in the case of Jurkat cells. Liquid chromatography-mass spectrometry analysis of all samples (except for C4 and C9) revealed that C1, C2, C3, and C5 each had a single component. More importantly, fractions C2, C3, and C5, which were selective to Jurkat cells, also had the same retention time of 1.846min. Fractions C6 and C8 had two components, with C7 having four components. This study serves as a basis for further work to isolate and characterize potential anticancer agents from the fractions of extracts of T. tetraptera fruits.